Studying speech and swallowing development in children with SMA type 1
Part of Brain & nervous system, Genetic & congenital clinical trials.
This study looks at how speech, communication, and swallowing (“bulbar function”) develop in babies and children with SMA type 1. It aims to better understand what to expect over time for children who start approved SMA treatments early.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your child) have genetic test proof of SMA (5q type).
- Symptoms started when your child was 6 months old or younger.
- Your child is between birth and 18 years old.
- Your child is already receiving an approved SMA disease-modifying treatment.
- A parent or legal guardian can understand the study, sign consent, and follow the visit plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This research study asks parents and caregivers about their lived experiences caring for children with SMA type 1 (a rare genetic condition affecting muscle strength), particularly around feeding and communication. Your honest feedback helps doctors and nurses better understand and support families like yours.
This study uses wearable devices (like smartwatches or activity trackers) to monitor movement and motor development in young children with spinal muscular atrophy (SMA), a rare genetic condition affecting muscle strength. The goal is to see if wearables can track disease progression and treatment response better than traditional clinic visits.
This study creates a registry and clinical hub for adults with 5q spinal muscular atrophy (SMA). It aims to track health outcomes and improve care for people living with SMA.
This study is looking for children and teens with spinal muscular atrophy (SMA) who are already on a treatment like Spinraza, Evrysdi, or Zolgensma. The goal is to understand different forms of SMA and how the treatment affects them over time.
This Phase 1/2 study tests whether EXG001-307 is safe and may improve health in babies with spinal muscular atrophy (SMA) type 1. It mainly looks at safety first, and whether the treatment can help the body work better over time.
This study uses sensors on the skin to measure muscle activity during swallowing in children. It aims to understand normal swallowing patterns, which could help doctors identify swallowing problems in other children.
Hear when a new SMA1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.